专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008064259A3 SOLID DISPERSION COMPOSITION COMPRISING FLUVASTATIN 审中-公开
公开(公告)号：WO2008064259A3
公开(公告)日：2008-05-29
申请号：PCT/US2007/085293
申请日：2007-11-20
申请人： BIOKEY, INC. , CHOW, San-Laung , WONG, David , LIN, Edward , GARCIA, Damian , AGUILAR, Jose
发明人： CHOW, San-Laung , WONG, David , LIN, Edward , GARCIA, Damian , AGUILAR, Jose
IPC分类号： A61K9/16 , A61K9/50
摘要： A solid dispersion composition containing fluvastatin and a polymer is provided. Optionally, a surfactant is included. The fluvastatin appears to be amorphous and the solid dispersion composition enables fluvastatin to be constantly released over a time period.

2. 发明申请

WO2008039615A2 CONTROLLED RELEASE HYDROGEL FORMULATION 审中-公开
标题翻译：控制释放水凝胶配方
公开(公告)号：WO2008039615A2
公开(公告)日：2008-04-03
申请号：PCT/US2007/076551
申请日：2007-08-22
申请人： BIOKEY, INC. , CHOW, San-laung , WONG, David , GARCIA, Damian
发明人： CHOW, San-laung , WONG, David , GARCIA, Damian
IPC分类号： A61K31/47 , A61K31/496 , A61K9/14 , A61P43/00
CPC分类号： A61K9/2054 , A61K9/2027 , A61K9/2095 , A61K31/47 , A61K31/496
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as controlled release dosage compositions for hydrophobic active ingredients. In one aspect, the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a hydrophobic drug, an adjustable ratio of a non-cross linked hydrogel polymer and a non-gelling insoluble polymer. One example is a controlled release pharmaceutical composition which includes 1% to 80% of a therapeutically amount of cilostazol, 4% to 80% of a water-swelling hydrogel polymer, and 4% to 80% of a non-gelling insoluble polymer. In another aspect, a constant release profile of the pharmaceutical formulation is obtained. In another aspect, a zero degree release profile of the pharmaceutical formulation is obtained. Further, a method for treating intermittent claudication using the pharmaceutical formulation is provided.
摘要翻译：本发明的实施方案通常提供药物组合物，制备口服药物组合物的方法，例如用于疏水性活性成分的控释剂型组合物。一方面，本发明提供了一种药物制剂，其包含治疗有效量的疏水性药物，可调节比例的非交联水凝胶聚合物和非凝胶不溶性聚合物。一个实例是控释药物组合物，其包含1％至80％的治疗量的西洛他唑，4％至80％的水溶胀水凝胶聚合物和4％至80％的非胶凝不溶性聚合物。另一方面，获得药物制剂的恒定释放曲线。另一方面，获得药物制剂的零度释放曲线。此外，提供了使用该药物制剂治疗间歇性跛行的方法。

3. 发明申请

WO2007117314A2 METHODS AND FORMULATIONS FOR MAKING CONTROLLED RELEASE ORAL DOSAGE FORM 审中-公开
标题翻译：制备控制释放口服剂型的方法和制剂
公开(公告)号：WO2007117314A2
公开(公告)日：2007-10-18
申请号：PCT/US2006/061625
申请日：2006-12-05
申请人： BIOKEY, INC. , CHOW, San-laung , WONG, David , GARCIA, Damian
发明人： CHOW, San-laung , WONG, David , GARCIA, Damian
IPC分类号： A61K9/24
CPC分类号： A61K9/2886 , A61K9/284 , A61K9/2846
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include one or more surfactants and aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. The core may also include aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.
摘要翻译：本发明的实施方案通常提供药物组合物，制备口服药物组合物的方法，例如延长释放剂量组合物，以及治疗抗抑郁药或戒烟的方法。一方面，本发明提供了包含核心的药物制剂，包括安非他酮及其盐衍生物和涂层。涂层可以包括一种或多种不溶性药学上可接受的聚合物的表面活性剂和水分散体。核心还可以包括一种或多种不溶性药学上可接受的聚合物的水分散体。另一方面，本发明提供了制备和施用口服剂型（例如片剂）的药物组合物的方法。

4. 发明申请

WO2006053089A2 METHODS AND FORMULATIONS FOR MAKING PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION 审中-公开
标题翻译：制备含有支架的药物组合物的方法和制剂
公开(公告)号：WO2006053089A2
公开(公告)日：2006-05-18
申请号：PCT/US2005/040665
申请日：2005-11-08
申请人： BIOKEY, INC. , CHOW, San-Laung , WONG, David , GARCIA, Damian
发明人： CHOW, San-Laung , WONG, David , GARCIA, Damian
IPC分类号： A61K9/24
CPC分类号： A61K31/137 , A61K9/2013 , A61K9/2054 , A61K9/2846
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5 % to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.
摘要翻译：本发明的实施方案通常提供药物组合物，制备口服药物组合物的方法，例如延长释放剂量组合物，以及治疗抗抑郁药或戒烟的方法。一方面，本发明提供了包含核心的药物制剂，包括安非他酮及其盐衍生物和涂层。涂层可以包括约5％至约99％重量的药学上可接受的不依赖于pH的聚合物的涂层。涂层可以进一步包括表面活性剂涂层的约0.001重量％至约30重量％。另一方面，本发明提供了制备和施用口服剂型（例如片剂）的药物组合物的方法。

5. 发明申请

WO2008076841A1 PHARMACEUTICAL COMPOSITION FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR AND CEREBROVASCULAR DISEASES 审中-公开
标题翻译：用于减少与心血管和脑血管病相关的风险的药物组合物
公开(公告)号：WO2008076841A1
公开(公告)日：2008-06-26
申请号：PCT/US2007/087469
申请日：2007-12-13
申请人： BIOKEY, INC. , CHOW, San-laung , WONG, David
发明人： CHOW, San-laung , WONG, David
IPC分类号： A61K31/40 , A61K31/35 , A61K31/225
CPC分类号： A61K45/06 , A61K31/225 , A61K31/35 , A61K31/40 , A61K2300/00
摘要： Methods and compositions enable treating atherosclerosis and atherosclerotic related diseases and/or lowering the risk of developing atherosclerosis related diseases. The composition includes an antilipemic agent combined with a vasodilator and/or an inhibitor of platelet aggregation for treating cardiovascular and cerebrovascular related diseases. In one embodiment, a pharmaceutical composition includes ezetimibe and cilostazol and is administered to treat patients suffering from cardiovascular and cerebrovascular related diseases and/or offer protection to those at risk to develop atherosclerosis and related diseases.
摘要翻译：方法和组合物能够治疗动脉粥样硬化和动脉粥样硬化相关疾病和/或降低发展动脉粥样硬化相关疾病的风险。该组合物包括与用于治疗心血管和脑血管相关疾病的血管扩张剂和/或血小板聚集抑制剂组合的抗血药剂。在一个实施方案中，药物组合物包括依泽替米贝和西洛他唑，并且被施用以治疗患有心血管和脑血管相关疾病的患者和/或向处于发展动脉粥样硬化和相关疾病的风险者提供保护。

6. 发明申请

WO2004108162A2 PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING 审中-公开
标题翻译：药物组合物和治疗方法
公开(公告)号：WO2004108162A2
公开(公告)日：2004-12-16
申请号：PCT/US2004/015953
申请日：2004-05-21
申请人： BIOKEY, INC. , LIN, Jenny, Li-Ying , WONG, David , CHOW, San-Laung
发明人： LIN, Jenny, Li-Ying , WONG, David , CHOW, San-Laung
IPC分类号： A61K47/00
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K31/43 , A61K31/545 , A61K31/60 , A61K31/65 , A61K31/704 , A61K31/7048
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating infection. More particularly, the invention relates to formulations containing a drug and a carrier material. In one aspect, the invention provides a pharmaceutical formulation including a therapeutically active agent, from about 0.1% to about 4.9% by weight of a pharmaceutically acceptable polymer, and from about 0.1% to about 30% by weight of a pharmaceutically acceptable acid, wherein the pharmaceutical composition have a zero order release profile of the therapeutically active agent. In another aspect, the invention provides methods for preparing and administering a pharmaceutical antibiotic composition in oral dosage form, such as a tablet.
摘要翻译：本发明的实施方案通常提供药物组合物，制备口服药物组合物的方法，例如缓释剂型组合物，以及治疗感染的方法。更具体地，本发明涉及含有药物和载体材料的制剂。在一个方面，本发明提供药物制剂，其包含治疗活性剂，约0.1重量％至约4.9重量％的药学上可接受的聚合物和约0.1重量％至约30重量％的药学上可接受的酸，其中药物组合物具有治疗活性剂的零级释放曲线。另一方面，本发明提供了制备和施用口服剂型（例如片剂）的药用抗生素组合物的方法。

7. 发明申请

WO2010108077A3 CONTROLLED RELEASE PARTICULATES CONTAINING WATER-INSOLUBLE DRUG 审中-公开
公开(公告)号：WO2010108077A3
公开(公告)日：2010-09-23
申请号：PCT/US2010/027935
申请日：2010-03-19
申请人： BIOKEY, INC. , WONG, David , CHENG, Xiufang , CHOW, San-Laung
发明人： WONG, David , CHENG, Xiufang , CHOW, San-Laung
IPC分类号： A61K9/22 , A61K9/20 , A61K47/30 , A61K31/05
摘要： A pharmaceutical composition. The composition has a plurality of controlled release particulates. Each particulate includes a coating layer and a core partially coated with the coating layer, in which the core contains a water-insoluble drug 5-80 wt.% and a first polymer 0.2-80 wt.% and the coating layer contains the water-insoluble drug 0-50 wt.% and a second polymer 0.2-50 wt.%. Each of the first and second polymers, independently, is a water-insoluble polymer, an enteric polymer, or a combination thereof. A method of making the composition is also disclosed herein.

8. 发明申请

WO2012116066A1 CONTROLLED RELEASE HYDROGEL FORMULATION 审中-公开
标题翻译：控制释放水凝胶制剂
公开(公告)号：WO2012116066A1
公开(公告)日：2012-08-30
申请号：PCT/US2012/026122
申请日：2012-02-22
申请人： BIOKEY, INC. , CHOW, San-Laung , WONG, David
发明人： CHOW, San-Laung , WONG, David
IPC分类号： A61K9/50 , A61K9/14 , A61K31/497 , A01N43/42
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/47 , A61K31/496
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as controlled release dosage compositions for hydrophobic active ingredients. In one aspect, the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a hydrophobic drug, an adjustable ratio of a non-cross linked hydrogel polymer and a non-gelling insoluble polymer. One example is a controlled release pharmaceutical composition which includes 1% to 80% of a therapeutically amount of cilostazol, 4% to 80% of a water-swelling hydrogel polymer, and 4% to 80% of a non-gelling insoluble polymer. In another aspect, a constant release profile of the pharmaceutical formulation is obtained. In another aspect, a zero degree release profile of the pharmaceutical formulation is obtained. Further, a method for treating intermittent claudication using the pharmaceutical formulation is provided.
摘要翻译：本发明的实施方案通常提供药物组合物，制备口服药物组合物的方法，例如用于疏水性活性成分的控释剂组合物。一方面，本发明提供了包含治疗有效量的疏水性药物，非交联水凝胶聚合物和非胶凝不溶性聚合物的可调节比例的药物制剂。一个实例是控释药物组合物，其包含1％至80％的治疗量的西洛他唑，4％至80％的水溶胀性水凝胶聚合物和4％至80％的非胶凝不溶性聚合物。在另一方面，获得药物制剂的恒定释放曲线。另一方面，获得药物制剂的零度释放曲线。此外，提供了使用药物制剂治疗间歇性跛行的方法。

9. 发明公开

EP1811967A2 METHODS AND FORMULATIONS FOR MAKING PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION 审中-公开
标题翻译：方法和制剂药物组合物安非他酮生产
公开(公告)号：EP1811967A2
公开(公告)日：2007-08-01
申请号：EP05818240.3
申请日：2005-11-08
申请人： Biokey, Inc.
发明人： CHOW, San-Laung , WONG, David , GARCIA, Damian
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/36
CPC分类号： A61K31/137 , A61K9/2013 , A61K9/2054 , A61K9/2846
摘要： Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5 % to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

10. 发明申请

WO2011127217A1 STABILIZED CHEMICAL DEHYDRATION OF BIOLOGICAL MATERIAL 审中-公开
标题翻译：稳定化学生物材料的脱盐
公开(公告)号：WO2011127217A1
公开(公告)日：2011-10-13
申请号：PCT/US2011/031477
申请日：2011-04-06
申请人： GENVAULT CORPORATION , SAGHBINI, Michael , HOGAN, Michael , SHI, Chunnian , DALBY, Brian , WONG, David
发明人： SAGHBINI, Michael , HOGAN, Michael , SHI, Chunnian , DALBY, Brian , WONG, David
IPC分类号： B32B1/00 , B32B9/00
CPC分类号： C12Q1/6806 , A01N1/021 , C07K17/02 , C12N1/04 , C12N9/96 , G01N33/54313
摘要： The present invention provides compositions and methods that enable the stabilization and storage of samples by contacting a sample with an assembly of particles, and reducing the water activity level of the contacted sample. By reducing the water activity level of the sample, the assembly of particles minimizes the degradation of the sample. Stabilizers may or may not be added to the assembly of particles to further minimize the degradation of the sample. Subsequently to storage in the assembly of particles, the samples are recoverable by eluting the assembly of particles with a fluid solution. In one embodiment, the entire assembly of particles will dissolve into the solution. In another embodiment, only part of the assembly of particles will dissolve into the solution. The assembly of particles provides the advantage that while it is porous, it comprises non-porous particulate material.
摘要翻译：本发明提供了通过使样品与颗粒组合接触并降低接触样品的水活度水平来使样品稳定和储存的组合物和方法。通过降低样品的水分活度水平，颗粒的组装使样品的降解最小化。稳定剂可以或可以不被添加到颗粒组合中以进一步使样品的降解最小化。随后存储在颗粒的组装中，可以通过用流体溶液洗脱颗粒的组合来回收样品。在一个实施例中，颗粒的整个组件将溶解到溶液中。在另一个实施方案中，只有部分颗粒组合将溶解到溶液中。颗粒的组合提供了这样的优点：当它是多孔的时，其包括无孔颗粒材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式